AmbroSpray
01 Overview
AmbroSpray ® is indicated for the mucolytic treatment of acute and chronic bronchopulmonary diseases characterized by impaired mucous formation and transportation.
02 Details
| Indication | AmbroSpray ® is indicated for the mucolytic treatment of acute and chronic bronchopulmonary diseases characterized by impaired mucous formation and transportation. |
| Advantages: | UNIQUE & PATENTED formulation
AmbroSpray® has a unique and patented formulation. PRECISE Spray presentation with a pharmaceutical-metered pump that delivers exactly 10mg per spray pump. Allows the therapeutic dose of 90 mg per day (3 puffs 3 times per day). HIGHEST CONCETRATION Only ambroxol has a 5% concentration; Mucosolvan® has only 0.6%. Practical and Easy to Use Small bottle that can comfortably be carried and easily be used. CLINICALLY PROVEN EFFICACY OF THE API Very well-known API with certified clinical effect. AmbroSpray® bioequivalence study vs. Mucosolvan® syrup. |